Source: Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
N. Roche (Paris, France). Characterisation of clinical phenotypes is mandatory for the development of new drugs. Research Seminar 2014 - Human translational medicine: a key bridge for the development of new drugs for severe asthma, COPD and ILD

Member's Comments

No comment yet.

Related content which might interest you: Clinical implications and opportunities for new drug therapies Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications Year: 2008 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations Source: Eur Respir J, 55 (3) 1901957; 10.1183/13993003.01957-2019 Year: 2020 How to accelerate bringing new drugs to patients: role of clinical trials networks Source: International Congress 2019 – Rare lung diseases Year: 2019 Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting Source: International Congress 2016 – Airway biomarkers Year: 2016 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020 Clinical implications and novel therapies Source: International Congress 2018 – Accelerated ageing in lungs Year: 2018 COPD mechanisms: novel aspects and implications for new therapies Source: ERS Live 2007 Year: 2007 A critical evaluation of the relevance of different asthma phenotypes for clinical practice Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021 Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Pathophysiology and potential future therapeutic targets using preclinical models of COVID-19 Source: ERJ Open Res, 6 (4) 00405-2020; 10.1183/23120541.00405-2020 Year: 2020 COVID-19 vaccines: immunology, regulation and clinical management Source: Eur Respir Monogr 2021; 94: 244-260 Year: 2021 Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 The challenges of severe pneumonia: new pathogens, new drugs and new formulations Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 670-672 Year: 2016